Rhinitis medicamentosa – preventable disease
https://doi.org/10.21518/2079-701X-2019-20-27-30
Abstract
Aim of the study – analysis of modern ideas about the pathogenesis of rhinitis medicamentosa. The authors consider the factors causing changes in inflammatory nature and leading to rhinitis medicamentosa. The comparative estimation of modern means of pharmacotherapy was made. On the basis of literature and clinical research data, it is concluded that Otrivin has a much more gentle effect and contributes less to the development of rhinitis medicamentosa.
About the Authors
A. I. Kryukov
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology; N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Andrey I. Kryukov, Dr. of Sci. (Med), Professor, Chief External Expert in Otorhinolaryngology of the Moscow City Healthcare Department, Director of the State Budgetary Healthcare Institution, State Budgetary Healthcare Institution «L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology» of the Department of Healthcare of Moscow
18A-2, Zagorodnoe Highway, Moscow, 117152; 1, Ostrovityanova str., Moscow, 117997
A. B. Turovskiy
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology; V.V. Veresaev Municipal Clinical Hospital
Russian Federation
Russian Federation
Andrey B. Turovskiy, Dr. of Sci. (Med), Deputy Chief Physician for Treatment, State Budgetary Healthcare Institution of Moscow «V.V. Veresaev Municipal Clinical Hospital of the Department of Healthcare of Moscow»
18A-2, Zagorodnoe Highway, Moscow, 117152; 1,0 Lobnenskaya St., Moscow, 127644
I. G. Kolbanova
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology
Belarus
Belarus
Inna G. Kolbanova, Cand. of Sci. (Med), Senior Researcher at the Research Department of Upper Respiratory Pathology and Rhinofacial Surgery
18A-2, Zagorodnoe Highway, Moscow, 117152
K. M. Musayev
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology
Russian Federation
Russian Federation
Kamran M. Musayev, Postgraduate student of the Upper Respiratory Tract Pathology and Rhinofacial Aesthetic Surgery Department
18A-2, Zagorodnoe Highway, Moscow, 117152
A. B. Karasov
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology
Russian Federation
Russian Federation
Al’bert B. Karasov, Postgraduate student of the Upper Respiratory Tract Pathology and Rhinofacial Aesthetic Surgery Department
18A-2, Zagorodnoe Highway, Moscow, 117152
References
1. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., Lang D.M., Nicklas R.A., Oppenheimer J., Portnoy J.M., Randolph C.C., Schuller D., Spector S.L., Tilles S.A. Joint Task Force on Practice. American Academy of Allergy. Asthma & Immunology. American College of Allergy. Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin. Immunol. 2008;122(2 Suppl):1-84. doi:10.1016/j.jaci.2008.06.003.
2. Ramey J.T., Bailen E., Lockey R.F. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-55. Available at: https://www. ncbi.nlm.nih.gov/pubmed/16784007.
3. Mortuaire G., de Gabory L., François M., Massé G., Bloch F., Brion N., Jankowski R., Serrano E. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137-44. doi: 10.1016/j.anorl.2012.09.005.
4. Graf P. Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. Clin Ther. 1999;21(10):1749-55. doi: 10.1016/S0149-2918(99)80053-8.
5. Blue J.A. Rhinitis medicamentosa. Ann Allergy. 1968;26(8):425-9. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538318/.
6. Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997;52(40 Suppl):28-34. doi: 10.1111/j.1398-9995.1997. tb04881.x.
7. Lockey R.F. Rhinitis medicamentosa and the stuffy nose. J Allergy Clin Immunol. 2006;118(5):1017-1018. doi: 10.1016/j.jaci.2006.06.018.
8. Graf P., Hallén H. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Laryngoscope. 1996;106(5 Pt 1):605-609. doi: 10.1097/00005537199605000-00016.
9. Scadding G.K. Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. Clin Ther. 2000;22(7):893-5. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10945515.
10. Bernstein I.L. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol. 2000;105(1 Pt 1):39-44. doi: 10.1016/s0091-6749(00)90175-1.
Review
For citations:
Kryukov AI, Turovskiy AB, Kolbanova IG, Musayev KM, Karasov AB. Rhinitis medicamentosa – preventable disease. Meditsinskiy sovet = Medical Council. 2019;(20):27-30. (In Russ.) https://doi.org/10.21518/2079-701X-2019-20-27-30
Views:
849
Email this article 